A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The reticulocyte production index (RPI), also called a corrected reticulocyte count (CRC), is a calculated value used in the diagnosis of anemia. This calculation is necessary because the raw reticulocyte count is misleading in anemic patients. The problem arises because the reticulocyte count is not really a count but rather a percentage: it reports the number of reticulocytes as a percentage of the number of red blood cells. In anemia, the patient's red blood cells are depleted, creating an erroneously elevated reticulocyte count.
Shiga toxin type 1 and type 2 (Stx-1 and 2) are the Shiga toxins produced by some E. coli strains. Stx-1 is identical to Stx of Shigella spp. or differs by only one amino acid. Stx-2 shares 55% amino acid homology with Stx-1. Cytotoxins – an archaic denotation for Stx – is used in a broad sense. Verocytotoxins/verotoxins – a seldom-used term for Stx – is from the hypersensitivity of Vero cells to Stx. The term Shiga-like toxins is another antiquated term which arose prior to the understanding that Shiga and Shiga-like toxins were identical.
However, there is no real demand in chemistry, physics, or engineering for isolating 234U, and the small amounts that may be wanted for research can be separated chemically from plutonium-238 that have been aged enough to accumulate its alpha decay product, which is 234U. Enriched uranium contains more 234U than natural uranium as a byproduct of the uranium enrichment process aimed at obtaining uranium-235, which concentrates lighter isotopes even more strongly than it does 235U. IAEA research paper TECDOC-1529 concludes the 234U content of enriched fuel is directly proportional to the degree of 235U—enrichment with 2% 235U resulting in 150 g 234U/ton HM (heavy metals, special meaning, relating to nuclear fuels), and the most common 4.5% 235U enrichment resulting in 400 g 234U/ton HM. The increased percentage of 234U in enriched natural uranium is not harmful to the operation of current nuclear reactors. Uranium-234 has a neutron-capture cross section of about 100 barns for thermal neutrons, and about 700 barns for its resonance integral—the average of neutrons having a range of intermediate energies. In a nuclear reactor non-fissile isotopes 234U and 238U both capture a neutron, thereby breeding fissile isotopes 235U and 239Pu, respectively. 234U is converted to 235U more easily and therefore at a greater rate than 238U is to 239Pu (via neptunium-239) because 238U has a much smaller neutron-capture cross section of just 2.7 barns.
Sitagliptin/simvastatin, sold under the brand name Juvisync, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes and hypercholesterolemia. It contains sitagliptin and simvastatin. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and simvastatin is an HMG-CoA reductase inhibitor. These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck. Juvisync was later removed from the market in 2013, due to business reasons.
The US Navy then sent two destroyers and an amphibious transport dock to the area to ensure that shipping could continue unabated. These vessels were then attacked with AShMs on three separate occasions, with no success. Though these attacks demonstrated the Houthis' limited ability to threaten vessels in Yemen's surrounding seas, the threat posed by them has since evolved significantly. Armed with a variety of anti-ship ballistic missiles and rockets that can be notoriously difficult to intercept and cover large areas, the next round of maritime clashes with the navies of the United Arab Emirates, Saudi Arabia, and the United States could have a completely different outcome. The Houthis have also hinted at using their extensive arsenal of loitering munitions against commercial shipping in the Red Sea, a tactic similar to recent Iranian tactics in the Persian Gulf. Patrol boats were fitted with anti-tank guided missiles, about 30 coast-watcher stations were set up, disguised "spy dhows" were constructed, and the maritime radar of docked ships used to create targeting solutions for attacks. One of the most notable features of the Houthis' naval arsenal became its remote-controlled drone boats which carry explosives and ram enemy warships. Among these, the self-guiding Shark-33 explosive drone boats originated as patrol boats of the old Yemeni coast guard. In addition, the Houthis have begun to train combat divers on the Zuqar and Bawardi islands.
Sources: en.wikipedia.org
In podzol soils, after conversion of softwood to hardwood forest or after earthworm invasion, these animals can obliterate the characteristic banded appearance of the soil profile by mixing the organic (LFH), eluvial (E) and upper illuvial (B) horizonss to create a single dark Ap horizon. Earthworms accelerate nutrient cycling in the soil-plant system through fragmention and mixing, physical grinding and chemical digestion of plant debris. However, the earthworm's existence cannot be taken for granted. Dr. W. E. Shewell-Cooper observed "tremendous numerical differences between adjacent gardens", and worm populations are affected by a host of environmental factors, many of which can be influenced by good management practices on the part of the gardener or farmer. Darwin estimated that arable land contains up to 53,000 per acre (130,000/ha) of worms, but more recent research has produced figures suggesting that even poor soil may support 250,000 per acre (620,000/ha), whilst rich fertile farmland may have up to 1,750,000 per acre (4,300,000/ha), meaning that the weight of earthworms beneath a farmer's soil could be greater than that of the livestock upon its surface. Richly organic topsoil populations of earthworms are much higher, averaging 500 per square metre (46/sq ft) and up to 400 g/m2, such that, for the 7 billion of us, each person alive today has support of 7 million earthworms. The ability to break down organic materials and excrete concentrated nutrients makes the earthworm a functional contributor in restoration projects.
=== MALDI-TOF === The same research group that developed COLD-PCR and used it to compare the sensitivity of regular PCR for genotyping with direct Sanger sequencing, RFLP, and pyrosequencing, also ran a similar study using MALDI-TOF as a downstream application for detecting mutations. Their results indicated that COLD-PCR could enrich mutation sequences from a mixture of DNA by 10–100 fold and that mutations with an initial prevalence of 0.1–0.5% would be detectable. Compared to the 5–10% low-level detection rate expected with traditional PCR.
Being one of the biggest donors to the WHO, the country's unpaid fees of estimated $260 million has already caused massive job losses at the organization. However, as a response, Washington said they saw no reason to comply. Ronald G. Nahass, president of the Infectious Diseases Society of America (IDSA), criticized the withdrawal, calling it "a shortsighted and misguided abandonment of our global health commitments" and "scientifically reckless". He emphasized that "It fails to acknowledge the fundamental natural history of infectious diseases" and that "Global cooperation and communication are critical to keep our own citizens protected because germs do not respect borders," adding that global cooperation is "not a luxury" but a "biological necessity".
== Behaviour and ecology == Emus are diurnal birds and spend their day foraging, preening their plumage with their beak, dust bathing and resting. They are generally gregarious birds apart from the breeding season, and while some forage, others remain vigilant to their mutual benefit. They are able to swim when necessary, although they rarely do so unless the area is flooded or they need to cross a river.
Thiamine: Thiamine acts as an essential cofactor in glucose metabolism, therefore, it may modulate diabetic complications by controlling glycemic status in diabetic patients. Additionally, deficiency of thiamine was observed to be associated with dysfunction of β-cells and impaired glucose tolerance. Different studies indicated possible role of thiamin supplementation on the prevention or reversal of early stage diabetic nephropathy, as well as significant improvement on lipid profile.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.